Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
This article was originally published in The Pink Sheet Daily
Executive Summary
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.
You may also be interested in...
Several Prostate Cancer Drug Candidates Heading Into Home Stretch
In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010
Several Prostate Cancer Drug Candidates Heading Into Home Stretch
In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010
Several Prostate Cancer Drug Candidates Heading Into Home Stretch
In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010.